Robert Millham

2.2k total citations · 1 hit paper
20 papers, 1.6k citations indexed

About

Robert Millham is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Robert Millham has authored 20 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Robert Millham's work include Colorectal Cancer Treatments and Studies (5 papers), Lung Cancer Treatments and Mutations (5 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Robert Millham is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Lung Cancer Treatments and Mutations (5 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Robert Millham collaborates with scholars based in United States, Spain and Italy. Robert Millham's co-authors include Amarnath Sharma, Jesús Gómez-Navarro, Antoni Ribas, James M. Reuben, C. A. Bulanhagui, Gabriel Lopez‐Berestein, Charla A. Parker, John A. Glaspy, Begoña Comı́n-Anduix and Dmitri Pavlov and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Robert Millham

20 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

2006 504 citations Jean W. Lee, Viswanath Devanarayan et al. Pharmaceutical Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Millham United States	12	797	658	638	330	127	20	1.6k
Kari Kendra United States	26	1.5k 1.9×	600 0.9×	1.1k 1.7×	319 1.0×	158 1.2×	119	2.5k
Paula Kaplan‐Lefko United States	13	557 0.7×	348 0.5×	620 1.0×	345 1.0×	92 0.7×	26	1.3k
Michael J. Campa United States	20	595 0.7×	726 1.1×	827 1.3×	274 0.8×	181 1.4×	56	1.8k
Sriram Subramaniam United States	16	694 0.9×	330 0.5×	366 0.6×	412 1.2×	151 1.2×	27	1.4k
Rosemary L. Balleine Australia	23	791 1.0×	291 0.4×	649 1.0×	187 0.6×	118 0.9×	58	2.0k
Jürgen R. Fischer Germany	25	972 1.2×	498 0.8×	704 1.1×	632 1.9×	48 0.4×	70	1.9k
Rebecca Marnocha United States	17	476 0.6×	208 0.3×	726 1.1×	260 0.8×	118 0.9×	35	1.3k
Dong Yang China	19	553 0.7×	328 0.5×	503 0.8×	249 0.8×	34 0.3×	53	1.2k
Kathleen D. Whitney United States	16	695 0.9×	239 0.4×	775 1.2×	135 0.4×	82 0.6×	25	1.6k
Roderick T. Bunch United States	15	721 0.9×	269 0.4×	591 0.9×	147 0.4×	68 0.5×	30	1.4k

Countries citing papers authored by Robert Millham

Since Specialization

Citations

This map shows the geographic impact of Robert Millham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Millham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Millham more than expected).

Fields of papers citing papers by Robert Millham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Millham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Millham. The network helps show where Robert Millham may publish in the future.

Co-authorship network of co-authors of Robert Millham

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Millham. A scholar is included among the top collaborators of Robert Millham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Millham. Robert Millham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Calvo, Emiliano, Jean‐Charles Soria, Wen Wee, et al.. (2016). A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clinical Cancer Research. 23(5). 1177–1185. 29 indexed citations

Shapiro, Geoffrey I., Katherine M. Bell‐McGuinn, Julian R. Molina, et al.. (2015). First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clinical Cancer Research. 21(8). 1888–1895. 97 indexed citations

Britten, Carolyn D., Alex A. Adjei, Robert Millham, et al.. (2014). Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Investigational New Drugs. 32(3). 510–517. 66 indexed citations

Britten, Carolyn D., Zev A. Wainberg, Josep Tabernero, et al.. (2012). 358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer. European Journal of Cancer. 48. 109–109. 10 indexed citations

Canon, J-L., Jonas Bergh, Cristina Saura, et al.. (2012). Abstract OT2-3-02: Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase Ib preliminary data.. Cancer Research. 72(24_Supplement). OT2–3. 3 indexed citations

Dowsett, Mitch, María Koehler, Robert Millham, et al.. (2012). 104P Phase II Randomized Study of Pre-Operative Pf-04691502 Plus Letrozole Compared with Letrozole (L) In Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer (Bc). Annals of Oncology. 23. ii44–ii44. 5 indexed citations

Jänne, Pasi A., David S. Boss, D. Ross Camidge, et al.. (2011). Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors. Clinical Cancer Research. 17(5). 1131–1139. 149 indexed citations

Millham, Robert, Brett E. Houk, Gary Borzillo, et al.. (2011). Abstract A167: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology.. Molecular Cancer Therapeutics. 10(11_Supplement). A167–A167. 13 indexed citations

Millham, Robert, Brett A. Houk, Gary Borzillo, et al.. (2011). Abstract B163: First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology.. Molecular Cancer Therapeutics. 10(11_Supplement). B163–B163. 4 indexed citations

10.

Shapiro, Geoffrey I., Julian R. Molina, Johanna C. Bendell, et al.. (2010). 387 First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics. European Journal of Cancer Supplements. 8(7). 123–123. 3 indexed citations

11.

Hixon, Mary L., et al.. (2010). Development of Inhibitors of the IGF-IR/PI3K/Akt/mTOR Pathway. Reviews on Recent Clinical Trials. 5(3). 189–208. 35 indexed citations

12.

Calvo, Emiliano, A. W. Tolcher, María Jesús Cancelo Hidalgo, et al.. (2010). Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs).. Journal of Clinical Oncology. 28(15_suppl). 3026–3026. 5 indexed citations

13.

Heo, D. S., et al.. (2010). PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study.. Journal of Clinical Oncology. 28(15_suppl). 7599–7599. 20 indexed citations

14.

Britten, Carolyn D., Alex A. Adjei, Robert Millham, et al.. (2010). 383 First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics. European Journal of Cancer Supplements. 8(7). 121–122. 3 indexed citations

15.

Jänne, Pasi A., Jan H.M. Schellens, Jeffrey A. Engelman, et al.. (2008). Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. Journal of Clinical Oncology. 26(15_suppl). 8027–8027. 53 indexed citations

16.

Yin, Donghua, Franzanne Vreeland, Larry J. Schaaf, et al.. (2007). Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy. Clinical Cancer Research. 13(3). 1000–1009. 56 indexed citations

17.

Ribas, Antoni, Douglas C. Hanson, Dennis A. Noe, et al.. (2007). Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer. The Oncologist. 12(7). 873–883. 136 indexed citations

18.

Lee, Jean W., Viswanath Devanarayan, Yu Chen Barrett, et al.. (2006). Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement. Pharmaceutical Research. 23(2). 312–328. 504 indexed citations breakdown →

19.

Millham, Robert, Dmitri Pavlov, Paul C. Canniff, et al.. (2006). Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206). Journal of Clinical Oncology. 24(18_suppl). 2542–2542. 3 indexed citations

20.

Ribas, Antoni, Luis H. Camacho, Gabriel Lopez‐Berestein, et al.. (2005). Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206. Journal of Clinical Oncology. 23(35). 8968–8977. 439 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact